Home / Companies / Boehringer Ingelheim
Company family · HQ DE
Boehringer Ingelheim: medicine shortages
As of 2 Nov 2026, 26 Boehringer Ingelheim products have a reported shortage across 4 countries, covering 5 medicines.
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Long-run trend in Canada
Canada dashboardCanada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Afatinib | 6 | 31 Jan 2027 | Not stated | 1/16 | |
| Dabigatran Etexilate | 6 | 1 Oct 2026 | Commercial decision or withdrawal | 10/16 | |
| Telmisartan and Amlodipine | 5 | 30 May 2025 | Manufacturing problem | 3/16 | |
| Linagliptin | 2 | 4 Mar 2024 | Increased demand | 1/16 | |
| Epinastine | 1 | 5 Jun 2026 | Quality problem or recall | 1/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.